Literature DB >> 11711632

Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.

U F Power1, T Huss, V Michaud, H Plotnicky-Gilquin, J Y Bonnefoy, T N Nguyen.   

Abstract

A BALB/c mouse model of enhanced pulmonary pathology following vaccination with formalin-inactivated alum-adsorbed respiratory syncytial virus (FI-RSV) and live RSV challenge was used to determine the type and kinetics of histopathologic lesions induced and chemokine gene expression profiles in lung tissues. These data were compared and contrasted with data generated following primary and/or secondary RSV infection or RSV challenge following vaccination with a promising subunit vaccine, BBG2Na. Severe peribronchiolitis and perivascularitis coupled with alveolitis and interstitial inflammation were the hallmarks of lesions in the lungs of FI-RSV-primed mice, with peak histopathology evident on days 5 and 9. In contrast, primary RSV infection resulted in no discernible lesions, while challenge of RSV-primed mice resulted in rare but mild peribronchiolitis and perivascularitis, with no evidence of alveolitis or interstitial inflammation. Importantly, mice vaccinated with a broad dose range (20 to 0.02 microg) of a clinical formulation of BBG2Na in aluminium phosphate demonstrated histopathology similar to that observed in secondary RSV infection. At the molecular level, FI-RSV priming was characterized by a rapid and strong up-regulation of eotaxin and monocyte chemotactic protein 3 (MCP-3) relative gene expression (potent lymphocyte and eosinophil chemoattractants) that was sustained through late time points, early but intermittent up-regulation of GRO/melanoma growth stimulatory activity gene and inducible protein 10 gene expression, while macrophage inflammatory protein 2 (MIP-2) and especially MCP-1 were up-regulated only at late time points. By comparison, primary RSV infection or BBG2Na priming resulted in considerably lower eotaxin and MCP-3 gene expression increases postchallenge, while expression of lymphocyte or monocyte chemoattractant chemokine genes (MIP-1beta, MCP-1, and MIP-2) were of higher magnitude and kinetics at early, but not late, time points. Our combined histopathologic and chemokine gene expression data provide a basis for differentiating between aberrant FI-RSV-induced immune responses and normal responses associated with RSV infection in the mouse model. Consequently, our data suggest that BBG2Na may constitute a safe RSV subunit vaccine for use in seronegative infants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711632      PMCID: PMC116138          DOI: 10.1128/JVI.75.24.12421-12430.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus.

Authors:  B Olszewska-Pazdrak; A Casola; T Saito; R Alam; S E Crowe; F Mei; P L Ogra; R P Garofalo
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection.

Authors:  S Becker; J M Soukup
Journal:  Immunobiology       Date:  1999-09       Impact factor: 3.144

4.  Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation.

Authors:  B Qiu; K A Frait; F Reich; E Komuniecki; S W Chensue
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

Authors:  L Goetsch; H Plotnicky-Gilquin; T Champion; A Beck; N Corvaïa; S Stâhl; J Y Bonnefoy; T N Nguyen; U F Power
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

6.  Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice.

Authors:  J B Domachowske; C A Bonville; K D Dyer; A J Easton; H F Rosenberg
Journal:  Cell Immunol       Date:  2000-03-15       Impact factor: 4.868

7.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  Respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Hughes; A P Collins
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

9.  Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.

Authors:  F Vaux-Peretz; J M Chapsal; B Meignier
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  Inhibitory effect of ferulic acid and isoferulic acid on the production of macrophage inflammatory protein-2 in response to respiratory syncytial virus infection in RAW264.7 cells.

Authors:  S Sakai; H Kawamata; T Kogure; N Mantani; K Terasawa; M Umatake; H Ochiai
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

View more
  17 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus.

Authors:  Yan Huang; Robert Anderson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Acute respiratory infection with mouse adenovirus type 1.

Authors:  Jason B Weinberg; Gregory S Stempfle; John E Wilkinson; John G Younger; Katherine R Spindler
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  Respiratory syncytial virus induces insensitivity to beta-adrenergic agonists in mouse lung epithelium in vivo.

Authors:  Ian C Davis; Anna Xu; Zhiqian Gao; Judy M Hickman-Davis; Phillip Factor; Wayne M Sullender; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-04-13       Impact factor: 5.464

7.  CD4+ T Cells Drive Lung Disease Enhancement Induced by Immunization with Suboptimal Doses of Respiratory Syncytial Virus Fusion Protein in the Mouse Model.

Authors:  Kirsten Schneider-Ohrum; Angie Snell Bennett; Gaurav Manohar Rajani; Leigh Hostetler; Sean K Maynard; Michelle Lazzaro; Lily I Cheng; Terrence O'Day; Corinne Cayatte
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

8.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

Review 10.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Authors:  Patricio L Acosta; Mauricio T Caballero; Fernando P Polack
Journal:  Clin Vaccine Immunol       Date:  2015-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.